Abstract: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.

Abstract: Pleuromutilin compounds of the formula (A) & (B) are of use in anti-bacterial therapy.

Abstract: Compositions for mole control comprise an active ingredient capable of repelling moles prepared such that it can be distributed in a solid form over the mole-invaded areas.

Abstract: Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

Abstract: Using an animal model, transgenic animals that do not express functional SR-BI and apoE which develop severe atherosclerosis, by age four weeks in transgenic mice, a class of drugs, PROBUCOL (4,4′-(isopropylidenedithio) bis(2,6-di-tert-butylphenol)) and monoesters of PROBUCOL, and BO 653, 2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butyl-benzofuran, has been discovered which is useful in normalizing abnormal lipoprotein levels and/or characteristics, such as those found in lipoprotein X-associated disease. These animals are good models for screening of drugs useful in the treatment and/or prevention of cardiac fibrosis, myocardial infarction, defects in electrical conductance, atherosclerosis, unstable plaque, and stroke, as well as for lipoprotein disorders such as cholestasis and lipoprotein X associated disorders.

Abstract: A vehicle for applying chemical compounds to wood comprises the following components in the indicated approximate percentages by weight of the total: toluene (40-70%), xylene (6-40%), benzophenone (3-18%), butyl glycol (2-9%), cetyl acetate (1-7%) and methanol (0.3-4%). The vehicle has a high wood penetration index and can be used for preparing compositions containing one or more chemical compounds useful for treating wood, for example insecticides and/or fungicides, for the purpose of treating or preventing damage caused by the attack of biological agents harmful for wood.

Abstract: A preferred emulsifier blend includes ethoxylated alcohols containing hydrocarbons of C10-C16 and preferably having on average at least 2.8 ethoxy and/or alcohol groups per chain and a glycerol mono- and/or dioleates, preferably in a ratio of from 9:1 to 4:6. These emulsion blends are particularly useful when mixed with hydroisomerized oils and water, for subsequent application as a spray oil to agricultural crops. The emulsion blends of the present invention also find particular utility when mixed with conventional spray oils and hard water.

Abstract: Cosmetic or pharmaceutical preparations comprising an oxalkylated polyglycerol ester of the formula (1) 1

Abstract: The present invention relates to the preparation and biological activity of 3-deoxy-Dmyo-inositol ether lipid analogs as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. The compounds of the present invention are useful as anti-tumor 5 agents which effectively inhibit the growth of mammalian cells.

Abstract: The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds.

Abstract: The present invention provides a pediculicidal and ovicidal composition with an extraordinarily lethal effectiveness that can also be used to remove parasites, such as lice. The pediculicidal and ovicidal composition contains a purified terpene agent such as citronellal, citronellol, citronellyl or a mixture thereof, a short chain alcohol, and a non-aqueous co-solvent and/or surfactant component. The composition more preferably utilizes citronellyl acetate as the active agent. The compositions can be administered topically to humans, animals or any infested areas.

Abstract: Derivatives of active ingredients with creatine and ornithine are disclosed having enhanced nutritional and/or therapeutic effects which favorably lend themselves to the preparation of orally administrable solid compositions.

Abstract: Disclosed is a method for treating ileus in a subject. The method comprises the step of administering to the subject an effective amount of an alpha-ketoalkanoic acid, a physiologically-acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid.

Abstract: Methods for increasing the bioavailability of certain orally administered pharmaceutical compounds by the coadministration of inhibitors of UDP-glucuronosyltransferase (UGT) are disclosed. Particular combinations of UGT inhibitors and pharmaceutical compound are described.

Abstract: The present invention relates to a cosmetic composition containing mineral water and one or more compounds selected from the group of creatine, pyruvic acid, and carnitine, and cosmetically acceptable salt or ester thereof.

Abstract: Rosacea is treated by application of a composition containing lipoic acid and/or a lipoic acid derivative such as dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures of any of these. Preferred compositions further comprise &agr;-hydroxy acids or acid derivatives such as glycolic and/or lactic acid. Other embodiments also contain fatty acid esters of ascorbic acid such as ascorbyl palmitate, and/or tocotrienol.

Abstract: The present invention is directed to a method of modulating the release of at least one endogenous compound in vivo. The method comprises delivering intranasally at least one micro-construct comprising an agonist and a pharmaceutically acceptable carrier to a locus comprising an agonist receptor and a heterologous receptor that is coupled to at least one common signaling molecule. The micro-construct used in the present inventive method provides sustained release of the agonist provided by erosion of an exterior surface defined by the micro-construct. Once released, the agonist effectively up- or down-regulates at least one signaling molecule common to both the agonist receptor and the heterologous receptor, thereby potentiating or desensitizing the heterologous receptor in order to modulate release of at least one endogenous compound under the control of the heterologous receptor.

Abstract: The present invention relates to insect repellant compositions containing, based upon the total weight of the composition, from about 6 to about 30 percent by weight of insect repellant active material having functionality selected from ester, amide, urethane or combinations thereof; from about 5 to about 30 percent by weight of alcohol, and from about 1 to about 10 percent by weight of nonionic surfactant. The compositions of the invention exhibit reduced rates of degradation of the active material in solution and are less drying and irritating to sensitive skin.

Abstract: The invention relates to a process for producing medicaments which comprise HMG CoA reductase inhibitors in the form of their salts, characterized in that the corresponding precursors of the actual active compounds are converted with bases, which contain alkali metal or alkaline earth metal ions, in a solvent, into the active compound, and the resulting active compound-containing solution is processed into the desired administration form.

Abstract: The present invention relates to a prolactin lowering drug containing at least one bicyclic diterpene of the labdane or clerodane type: wherein R1=H, C1 to C3 alkyl or C1 to C3 acyl.

Abstract: New enone derivatives and conjugates are described. These compounds can be used as cancer therapeutics.

Abstract: Provided are novel DT- and ETA-based immunotoxins and a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease.

Abstract: The present invention provides a prophylactic and therapeutic medicament for ophthalmic diseases, especially ophthalmic inflammatory diseases and corneal ulcer, comprising as an active ingredient a compound represented by the formula (I): or a pharmacologically acceptable salt or hydrate thereof.

Abstract: The invention is directed primarily to compounds of Formula I: wherein: R1 is a polymeric residue; L1 is a bifunctional linking group; Y1 and Y2 are independently O, S or NR7; R2-7 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy; D is a moiety that is a leaving group or a residue of a compound to be delivered into a cell; Z is selected from the group consisting of: a moiety that is actively transported into a target cell, a hydrophobic moiety, and combinations thereof; Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group; and (y) is a positive integer greater than or equal to 1. Methods of making and using the same are also disclosed.

Abstract: The present invention relates to a topical composition, comprising

Abstract: Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.

Abstract: Choline derivatives useful in the treatment of the diseases related with central cholinergic deficit

Abstract: There are disclosed compositions for oral administration of a novel pharmaceutical composition, which includes xanthine-based stimulants, various neurotransmitter precursors, minerals, nootropic herbs, and amino acids capable of augmenting the preparation. Also, embodied in these compositions are specific cerebral vasodilators and cognition enhancing neurosteroids.

Abstract: The present invention relates to topical skin care compositions having improved stability containing a retinoid and a non-paraben preservative and being substantially free of paraben preservatives. Preferred non-paraben preservatives include phenols, phenol salts, carboxylic acids, carboxylic acid salts, quaternium ammonium compounds, halogens, halogen salts, alcohols, inorganic salts, heterocyclic compounds, emulsifying preservatives, and mixtures thereof. The present invention also relates to methods of using such compositions to regulate the condition of skin and/or hair.

Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

Abstract: Novel compositions of matter containing aromatic compounds and terpenoids which are present in and may preferably be derived from the plant Alpinia galanga (Zingiberaceae) show synergistic effects with respect to immunomodulation, and they significantly suppress hypersensitivity reactions. Thus they are used for preparing medicaments for these purposes and, more specifically, for the treatment or prevention of IgE mediated allergic reactions and conditions, such as asthma, allergic rhinitis, atopic eczema or anaphylaxis, and autoimmune disorders, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis or psoriasis, as well as for the alleviation of pain. They can for example be formulated into pharmaceuticals, cosmetics or dietary supplements. A method of preparing such compositions from Alpinia galanga is also described.

Abstract: The present invention relates to method of treatment of fungal infection with a synergistic combination of plant compounds useful for enhancing the activity of antifungal compounds. The plant compounds menthol and menthyl acetate when mixed at specific concentrations enhances the antifungal activity of the commercially available fungicides.

Abstract: Methods for identifying and monitoring increased or decreased levels of inducible nitric oxide synthase in biological samples are provided. A collection device for detecting inducible nitric oxide synthase in biological samples is also provided. Detection of inducible nitric oxide synthase is useful in the diagnosis of inflammatory responses such as infections mediated by bacteria, yeast or viruses, transplant rejection, rheumatoid arthritis, interstitial cystitis and cancer.

Abstract: When a communication disruptant containing (Z)-11-tetradecen-1-yl acetate as the only active ingredient is continually used for a period of 5 to 10 years, a phenomenon has been observed in which its communication-disrupting effect on insect pests, particularly of the family Tortricidae, living in the field or the like through successive generations is reduced. Accordingly, it is eagerly desired to develop a new communication disruptant which is also effective for such fields where the communication-disrupting effect (on insect pests, particularly of the family Tortricidae, living there through successive generations) has been reduced.

Abstract: Cosmetic skin care methods and compositions containing methyl-branched esters. The inventive compositions provide control of sebum secretion from sebocytes, improved oil control and improved skin feel, prevent shine and stickiness, while also. providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photoaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin.

Abstract: The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by co-administration of metanicotine and at least one compound which exhibits antagonist activity, or both agonistic and antagonists activity, toward one or more nicotinic acetylcholine receptor subtypes. The subject invention, in another aspect, pertains to pharmaceutical compositions containing metanicotine and at least one compound which inhibits antagonistic activity, or both agonistic and antagonistic activity, toward one or more nicotinic acetylcholine receptor subtypes.

Abstract: The present invention includes a method for increasing meat production while reducing fat in ruminant and non-ruminant animals and for increasing egg production in poultry and milk production in ruminant animals. The method includes mixing ingredients that include 190 proof ethanol in a concentration of about 9% by weight of a food supplement with clay and a nitrogen source such as urea to form the food supplement. The food supplement for ruminant animals additionally includes a condensed distiller's soluble fraction. The mixed ingredients are added to an animal feed such as corn. The animal feed and supplement are fed to an animal at least one per day.

Abstract: A composition comprising cyclodextrin and an &agr;-hydroxy acid complexed by the cyclodextrin. A pharmaceutical preparation comprising a cyclodextrin-&agr;-hydroxy acid complex and a pharmaceutically acceptable adjuvant. A combination of a cyclodextrin/&agr;-hydroxy acid complex and an applicator having an applicator head with alternating grooves and ridges disposed on the applicator head. A method of treating a skin area comprising applying a cyclodextrin/&agr;-hydroxy acid complex to the skin area in a pharmaceutically effective amount.

Abstract: Compositions, generally useful for preserving the skin and/or improving its health and appearance, comprise a peptide copper complex and retinol, a retinol derivative, or a mixture thereof. In another embodiment, the disclosed compositions further comprise additives, including emollients, sunscreen agents, skin protectants, skin conditioning agents, and/or humectants. Also disclosed is a method for treating skin to accomplish such preservation and/or improvement thereof, where the method comprises the step of topically applying a disclosed composition to an area of skin in need of such treatment.

Abstract: A method for preventing or combating chapping, tautness and/or redness comprising topical application onto skin or mucous membranes of a composition comprising, in a physiologically acceptable medium, preferably from 0.00001 to 0.1% of a retinoid and/or a carotenoid, and preferably from 0.001 to 1% of acexamic acid or a salt thereof is provided.

Abstract: A composition of (Z)-11-tetradecenyl acetate and (Z)-11-tetradecenal in a weight ratio of about 50:50 to about 90:10 is a highly effective mating disruptant for the male Orange Tortrix and Omniverous Leafroller moths. In a preferred embodiment, the weight ratio of (Z)-11-tetradecenyl acetate and (Z)-11-tetradecenal is about 75:25. The composition demonstrates biological activity in the form of enhanced mating disruption efficacy that is greater than any discovery or development to date for the Orange Tortrix of the Omniverous Leafroller.

Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Abstract: Salicylamide derivatives represented by formulae (1a) and (1b); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae (1a) and (1b) are useful as anti-inflammatory agents and immunosuppressive agents which exert an effect of inhibiting the activation of NF-&kgr;B with little side effects.

Abstract: A method of and compositions for suppressing the growth of tumor cells in a patient are disclosed. In one embodiment, the method comprises treating the patient with an effective amount of an isoprenoid ether-linked compound, wherein the isoprenoid ether-linked compound comprises a first acyclic isoprenoid molecule linked via an ether linkage to a second molecule, wherein the second molecule can suppress tumor formation.

Abstract: Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.

Abstract: A pharmaceutical composition for the treatment of Inflammatory Disease or Respiratory Disease in mammals, which comprises, as active ingredients, a neutrophil elastase inhibitor and an sPLA2 inhibitor.

Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

Abstract: The invention provides methods and compositions useful for attracting predatory insects.

Abstract: This invention relates to new antiestrogens of the general formula in which the substituents have the meanings that are explained in more detail in the description. The new compounds are a) pure antiestrogens or b) antiestrogens with partial estrogenic action (tissue-selective estrogens). Based on these properties, the new compounds are suitable for the production of pharmaceutical agents: in the case of a), for example, for the treatment of breast cancer; in the case of b), for example, for hormone replacement therapy.

Abstract: The invention relates to depot preparations for the targeted release of an aldehyde or ketone together with an alcohol and a carboxylic acid, where the released aldehydes or ketones are organoleptic substances, specifically fragrances or flavorings.